FDA Again Says PTC Therapeutics Duchenne Drug Is Unworthy of Approval

Sept. 26, 2017

According to the U.S. Food and Drug Administration, PTC Therapeutics has failed to supply persuasive evidence that its experimental Duchenne muscular dystrophy drug, ataluren, is effective.

PTC have spent the last year in an effort to bring the drug to market. The FDA has already refused to review ataluren twice because the drug failed to show effectiveness in clinical trials.

Read the Reuters report here